48 results about "Opioid overdose" patented technology

A system for automatically injecting naloxone into a patient, upon detection of physiological parameters indicative of an opioid overdose.

The invention relates to compositions and methods for attenuating opioid induced respiratory depression. Such compositions comprise opioids and sequestered opioid antagonists in a multi-particulate dosage formulation.

Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions.

There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

The invention provides storage stable sublingual formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the sublingual formulations of the present invention to a patient in need thereof.

Medical devices and methods for rapid and efficient systemic drug delivery via mucous membranes, particularly oral mucosae, are described. Use of such devices and methods are particularly easy for people without any medical training to employ should they be called upon to provide emergency medical treatment for a victim suffering from anaphylactic shock, opioid overdose, or other life-threatening events. In some embodiments, the device includes an applicator tip with a porous application layer positioned on the end of an elongate handle. The device may also include various means for disrupting a barrier to facilitate mixing of compounds, including an active ingredient, and permit flow of the compounds from a reservoir to the applicator tip.

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention both intranasally and sublingually to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally and sublingually the naloxone formulations of the present invention.

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt, or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence-, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

A novel dosage form for delivering an opioid antagonist such as naloxone is disclosed. The dosage form comprises an oral dissolvable film containing an amount of the opioid antagonist effective to reduce or counteract the effect of an opioid overdose in an individual. Methods of administering the dosage form to an individual experiencing an opioid overdose are also disclosed.

A device and method utilizing user operated actuators such as momentary switches, intermediate switches, accelerometers or video cameras to detect impaired consciousness as an early symptom of opioid overdose to then trigger administration of preloaded naloxone to rescue the user from an overdose.

An overdose of opioids can cause the user to stop breathing, resulting in death. A physiological monitoring system monitors respiration based on oxygen saturation readings from a fingertip pulse oximeter in communication with a smart mobile device and sends opioid monitoring information from the smart mobile device to an opioid overdose monitoring service. The opioid overdose monitoring service notifies a first set of contacts when the opioid monitoring information indicates a non-distress stats and notifies a second set of contact when the opioid monitoring information indicates an overdose event. The notification can be a phone call or text message to a specified person, emergency personnel, or first responders, and can include the location of the smart mobile device. The smart mobile device can also include the location of the nearest treatment center having emergency medication used in treating opioid overdose, such as naloxone.

Disclosed herein are various drug delivery systems, pharmaceutical compositions, dosage forms, and kits for providing opioid overdose rescue to a patient as well as a method for providing opioid overdose rescue to a patient. The drug delivery systems, pharmaceutical compositions, dosage forms, and kits may comprise an opioid antagonist and an antipsychotic agent.